General

Canada Lights up for Melanoma Month

0
Landmarks across Canada will be illuminated to recognize May, World Melanoma Month. MNC’s signature color Yellow will be used to…

Adjusting to COVID-19

0
Patient Perspective by kevin On February 13 of 2020, life got just a little bit more complicated. We were already…

Catherine’s Story

0
My story begins in 2006 with a metastatic melanoma Stage 4 located on my left ankle found by my general…

Message from MNC’s Board Chair – May 2020

0

Message from the Chair – This New Year brings great anticipation for progress in the treatment of melanoma and skin cancers, like cutaneous squamous cell carcinoma (cSCC). We have been anxiously awaiting provincial listings for adjuvant therapies for melanoma – in particular the adjuvant (for stage III fully resected patients), targeted therapy combination of Dabrafenib and Trametinib, and the adjuvant immunotherapies – Pembrolizumab and Nivolumab.

SUBSCRIBE


Sign up to receive the latest news from Melanoma Network of Canada

Menu